Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleClinical Investigation
Open Access

Estimating the Risk for Secondary Cancer After Targeted α-Therapy with 211At Intraperitoneal Radioimmunotherapy

Erik Leidermark, Andreas Hallqvist, Lars Jacobsson, Per Karlsson, Erik Holmberg, Tom Bäck, Mia Johansson, Sture Lindegren, Stig Palm and Per Albertsson
Journal of Nuclear Medicine January 2023, 64 (1) 165-172; DOI: https://doi.org/10.2967/jnumed.121.263349
Erik Leidermark
1Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden;
2Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreas Hallqvist
1Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden;
3Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lars Jacobsson
2Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Per Karlsson
1Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden;
3Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erik Holmberg
3Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; and
4Regional Cancer Center West, Sahlgrenska University Hospital, Gothenburg, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tom Bäck
2Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mia Johansson
1Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden;
3Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sture Lindegren
2Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stig Palm
2Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Per Albertsson
1Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden;
3Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 64 no. 1 165-172
DOI 
https://doi.org/10.2967/jnumed.121.263349
PubMed 
35798559

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication October 8, 2021
  • Revision received June 2, 2022
  • Published online January 4, 2023.

Article Versions

  • previous version (July 7, 2022 - 11:02).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2023 by the Society of Nuclear Medicine and Molecular Imaging. Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: https://creativecommons.org/licenses/by/4.0/. Details: http://jnm.snmjournals.org/site/misc/permission.xhtml.

Author Information

  1. Erik Leidermark1,2,
  2. Andreas Hallqvist1,3,
  3. Lars Jacobsson2,
  4. Per Karlsson1,3,
  5. Erik Holmberg3,4,
  6. Tom Bäck2,
  7. Mia Johansson1,3,
  8. Sture Lindegren2,
  9. Stig Palm*,2 and
  10. Per Albertsson*,1,3
  1. 1Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden;
  2. 2Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden;
  3. 3Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; and
  4. 4Regional Cancer Center West, Sahlgrenska University Hospital, Gothenburg, Sweden
  1. For correspondence or reprints, contact Per Albertsson (per.albertsson{at}oncology.gu.se).
  1. ↵* Contributed equally to this work.

View Full Text

Statistics from Altmetric.com

Cited By...

  • 5 Citations
  • 5 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Astatine-211 based radionuclide therapy: Current clinical trial landscape
    Per Albertsson, Tom Bäck, Karin Bergmark, Andreas Hallqvist, Mia Johansson, Emma Aneheim, Sture Lindegren, Chiara Timperanza, Knut Smerud, Stig Palm
    Frontiers in Medicine 2023 9
  • Gadolinium-Based Nanoparticles Sensitize Ovarian Peritoneal Carcinomatosis to Targeted Radionuclide Therapy
    Clara Diaz Garcia-Prada, Léna Carmes, Salima Atis, Ali Parach, Alejandro Bertolet, Marta Jarlier, Sophie Poty, Daniel Suarez Garcia, Wook-Geun Shin, Stanislas Du Manoir, Jan Schuemann, Olivier Tillement, François Lux, Julie Constanzo, Jean-Pierre Pouget
    Journal of Nuclear Medicine 2023 64 12
  • Astatine-211 Radiopharmaceuticals; Status, Trends, and the Future
    Mobina Rabiei, Mahboobeh Asadi, Hassan Yousefnia
    Current Radiopharmaceuticals 2024 17 1
  • Radioimmunotherapy for peritoneal carcinomatosis: Preclinical proof of concept to clinical translation
    Nicole Aguirre, Darren R. Veach, Andrea Cercek, Sarah M. Cheal, Steven M. Larson, Garrett M. Nash, Nai-Kong V. Cheung
    Cell Reports Medicine 2025 6 4
  • Targeted alpha-particle therapy – possibilities of post-therapeutic imaging
    Monika Tulik, Jolanta Kunikowska
    Polish Journal of Medical Physics and Engineering 2024 30 4

Article usage

Article usage: July 2022 to May 2025

AbstractFullPdf
Jul 202212620178
Aug 2022383052
Sep 2022271031
Oct 2022204030
Nov 2022112029
Dec 2022114024
Jan 2023396537156
Feb 202310038760
Mar 202310340038
Apr 20236328234
May 20235022539
Jun 20234623319
Jul 20233326218
Aug 20233032418
Sep 20233824122
Oct 20232510815
Nov 20234111825
Dec 2023187433
Jan 20244322430
Feb 20245219630
Mar 20241513333
Apr 2024185531
May 2024254018
Jun 2024284726
Jul 2024117944
Aug 2024146733
Sep 2024122816
Oct 2024124424
Nov 2024263424
Dec 202494937
Jan 2025214724
Feb 2025147222
Mar 2025105541
Apr 2025205130
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 64 (1)
Journal of Nuclear Medicine
Vol. 64, Issue 1
January 1, 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Estimating the Risk for Secondary Cancer After Targeted α-Therapy with 211At Intraperitoneal Radioimmunotherapy
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Estimating the Risk for Secondary Cancer After Targeted α-Therapy with 211At Intraperitoneal Radioimmunotherapy
Erik Leidermark, Andreas Hallqvist, Lars Jacobsson, Per Karlsson, Erik Holmberg, Tom Bäck, Mia Johansson, Sture Lindegren, Stig Palm, Per Albertsson
Journal of Nuclear Medicine Jan 2023, 64 (1) 165-172; DOI: 10.2967/jnumed.121.263349

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Estimating the Risk for Secondary Cancer After Targeted α-Therapy with 211At Intraperitoneal Radioimmunotherapy
Erik Leidermark, Andreas Hallqvist, Lars Jacobsson, Per Karlsson, Erik Holmberg, Tom Bäck, Mia Johansson, Sture Lindegren, Stig Palm, Per Albertsson
Journal of Nuclear Medicine Jan 2023, 64 (1) 165-172; DOI: 10.2967/jnumed.121.263349
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • Gadolinium-Based Nanoparticles Sensitize Ovarian Peritoneal Carcinomatosis to Targeted Radionuclide Therapy
  • Google Scholar

More in this TOC Section

  • [18F]FDG PET/CT Predicts Patient Survival in Patients with Systemic Sclerosis–Associated Interstitial Lung Disease
  • Whole-Body [18F]DPA-714 Kinetic Assessment Using PET/CT Scanner with Long Axial Field of View
  • Clinical Outcomes of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Skeletal Metastases from Neuroendocrine Tumors: Insights from Real-World Experience
Show more Clinical Investigation

Similar Articles

Keywords

  • secondary cancer
  • α-particle
  • targeted α-therapy
  • human
  • astatine-211
  • radium-224
SNMMI

© 2025 SNMMI

Powered by HighWire